Drugs / Ancestim
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00434239 | Feb 2007 → May 2011 | myelodysplastic syndrome | Peter MacCallum Cancer Centre, Australia | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00001750 | Sep 1998 → Aug 2002 | plasma cell myeloma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ancestim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00434239 ↗ |
| Known as | Stemgen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001750 ↗ |
| Modality | Protein / enzyme biologic | “Ancestim (recombinant human stem cell factor)” NCT00434239 ↗ |
| Route | Subcutaneous | “Ancestim s.c. injections” NCT00434239 ↗ |